Deep Track Capital’s Aligos Therapeutics ALGS Stock Holding History

Deep Track Capital’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56M	Hold	444,110	–	–	0.04%	67
2026 Q1	$3.3M	Hold	444,110	–	–	0.05%	63
2025 Q4	$4.14M	Hold	444,110	–	–	0.07%	50
2025 Q3	$4.35M	Hold	444,110	–	–	0.12%	49
2025 Q2	$3.2M	Hold	444,110	–	–	0.1%	60
2025 Q1	$3.66M	Buy	444,110 +200,000	+82%	+$4.38M	0.12%	63
2024 Q4	$9.73M	Hold	244,110	–	–	0.36%	48
2024 Q3	$2.11M	Sell	244,110 -1	-0%	-$12	0.07%	68
2024 Q2	$2.14M	Hold	244,111	–	–	0.06%	66
2024 Q1	$5.98M	Hold	244,111	–	–	0.17%	58
2023 Q4	$4.05M	Buy	+244,111	New	+$4.2M	0.14%	59

Other funds holding ALGS

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deep Track Capital's ALGS Position: Q2 2026 in Review

Deep Track Capital held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 444,110 shares worth $2.56M. The position accounts for 0.04% of the portfolio, ranked #67.

Deep Track Capital first reported a position in ALGS in Q4 2023 and has held it in 11 quarters since. The position peaked at $9.73M in Q4 2024. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Deep Track Capital held 444,110 shares of Aligos Therapeutics worth $2.56M as of Q2 2026.
Deep Track Capital left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up 0.04% of Deep Track Capital's portfolio in Q2 2026, its #67 holding.
Deep Track Capital first reported a position in Aligos Therapeutics in Q4 2023 and has held it in 11 quarters since.
Deep Track Capital's Aligos Therapeutics position peaked at $9.73M in Q4 2024.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.